The expression of Ki-67, but not proliferating cell nuclear antigen, predicts poor disease free survival in patients with adenocarcinoma of the lung

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4277-4282

  Oka, Soichi ^a   Uramoto, Hidetaka ^a   Shimokawa, Hidehiko ^a   Iwanami, Takashi ^a   Tanaka, Fumihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Adenocarcinoma; Ki 67; Lung; PCNA; Recurrence

Indexed keywords

CARBOPLATIN; CYCLINE; GEMCITABINE; KI 67 ANTIGEN; PACLITAXEL; UFT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECURRENCE;

EID: 84855167330     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Smith W and Khuri FR: The care of the lung cancer patient in the 21st century: a new age. Semin Oncol 31: 11-15, 2004. (Pubitemid 38609787)
2. Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet 355: 479-485, 2000. (Pubitemid 30085163)
3. Uramoto H, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Sakata H, Nakanishi K and Yasumoto K: A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer. Anticancer Res 30: 4695-4699, 2010.
4. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immuno 1133: 1710-1715, 1984. (Pubitemid 14035254)
5. Haerslev T, Jacobsen GK and Zedeler K: Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37: 101-113, 1996. (Pubitemid 26030089)
6. Mathews MB, Bernstein RM, Franza BR Jr and Garrels JI: Identity of the proliferating cell nuclear antigen and cyclin. Nature 309: 374-376, 1984. (Pubitemid 14145846)
7. Celis JE, Bravo R, Larsen PM and Fey SJ: A nuclear protein whose level correlates with the proliferative state of normal as well as transformed cells. Leuk Res 8: 143-147, 1984.
8. Ben-Izhak O, Bar-Chana M, Sussman L, Dobiner V, Sandbank J, Cagnano M, Cohen H and Sabo E: Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 41: 519-525, 2002. (Pubitemid 36693597)
9. Stuart-Harris R, Caldas C, Pinder SE and Pharoah P: Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32824 patients. Breast 17: 323-334, 2008.
10. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K and Yasumoto K: Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911, 2004. (Pubitemid 39383040)
11. Sugaya M, Uramoto H, Uchiyama A, Nagashima A, Nakanishi R, Sakata H, Nakanishi K, Hanagiri T and Yasumoto K: Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer. Anticancer Res 30: 3039-3044, 2010.
12. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, So T, Takenoyama M, Hanagiri T, Oyama T and Yasumoto K : Association between lymphangiogenesis/micrometastasis-andadhesion related molecules in resected stage I NSCLC. Lung Cancer 70: 320-328, 2010.
13. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 68: 198-203, 2010.
14. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol 5: 591-596, 2010.
15. Chu J-S, Huang C-S and Chang K-J: Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan. Cancer Lett 131: 145-152, 1998. (Pubitemid 28479782)
16. Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw P: International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 4: 1049-1059, 2009.
17. Burger PC, Shibata S and Kleihues P: Proliferation markers for neoplasms of the nervous system. In: RA Delellis (ed.). Advances in Immunohistochemistry. Raven Press, New York pp. 301-315, 1988.
18. Ogata K, Kurki P, Celis JE, Nakamura RM and Tan EM: Monoclonal antibodies to a nuclear protein (PCNA/ cyclin) associated with DNA relication. Exp Cell Res 168: 475-486, 1987. (Pubitemid 17012637)
19. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H and Masuda M: Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol 4: 32-42, 2010.